The Role of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease Diagnosis. Where are we Now?
Vasileios T. Papaliagkas
Pages 70-78 (9)
Alzheimer’s disease (AD) is a rapidly growing disease that is estimated to affect about 36 million people
worldwide, therefore there is an immediate need for its’ early diagnosis and treatment. A number of research studies are
performed on possible accurate and reliable diagnostic biomarkers of AD. This review study provides an update on the
cerebrospinal fluid (CSF) proteins that are being currently used in clinical practice and studied as biomarkers for early AD
diagnosis and their future prospects, as well as relevant patents.
Alzheimer’s disease (AD), Abeta42, cytochrome c, secretases, Tau.
Third Department of Neurology, G Papanikolaou Hospital, Exohi Thessaloniki, Greece.